UCLA Researchers & Innovators
Industry & Investors
News & Events
About
Concierge
Search Results - metabolic+diseases
15
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Creation of a Specified Probiotic Blend to Help with Weight Loss and Associated Metabolic Disease (UCLA Case No. 2023-258)
UCLA researchers in the Department of Medicine, Vatche and Tamar Manoukin Division of Digestive Diseases have developed a novel probiotic blend composed of two gut bacteria strains. This blend has the potential to be a safe supplement for treating food addiction, obesity, cognition, and other associated
metabolic diseases
in humans. BACKGROUND: Obesity...
Published: 11/18/2024
|
Inventor(s):
Arpana Church
Keywords(s):
bacterial strain
,
brain reward system
,
brain-gut microbiome
,
food addiction
,
food metabolism
,
gut-brain axis
,
Mental health
,
Metabolic Diseases
,
Nutraceuticals / Probiotics
,
nutritional supplement
,
obesity
Category(s):
Therapeutics > Metabolism And Endocrinology
,
Therapeutics > Gastroenterology
,
Therapeutics > Psychiatry And Mental Health
AAV-Based Treatment of Guanidinoacetate Methyltransferase (GAMT) Deficiency (UCLA Case No. 2021-012)
SUMMARY: UCLA researchers in the Departments Molecular & Medical Pharmacology and Surgery in the David Geffen School of Medicine have developed a novel and tissue-specific gene therapy treatment for Guanidinoacetate methyltransferase (GAMT) deficiency. BACKGROUND: Guanidinoacetate Methyltransferase (GAMT) deficiency is caused by a mutation in...
Published: 8/10/2023
|
Inventor(s):
Gerald Lipshutz
Keywords(s):
Adeno-associated viruses (AAV)
,
Creatine
,
GAMT deficiency
,
Gene Therapy
,
Metabolic Diseases
Category(s):
Therapeutics > Gene Therapy And Editing
,
Therapeutics > Genetic Diseases
,
Therapeutics > Metabolism And Endocrinology
2020-854 DUAL SELF-REGULATED DELIVERY OF INSULIN AND GLUCAGON BY A HYBRID PATCH
UCLA researchers have developed a novel hybrid microneedle patch that can deliver insulin and glucagon in a glucose-dependent manner. BACKGROUND: Type I diabetes (T1D) is an autoimmune disease in which pancreatic -cells are destroyed and there is a deficiency is insulin secretion. Type 2 diabetes (T2D) is a metabolic disorder resulting from insulin...
Published: 7/19/2023
|
Inventor(s):
Zhen Gu
Keywords(s):
Drug Delivery
,
Medical Devices and Materials
,
Metabolic Diseases
,
Other Polymers
,
Polymers
,
Therapeutics & Vaccines
Category(s):
Medical Devices
,
Platforms > Drug Delivery
,
Therapeutics
,
Platforms > Drug Delivery > Other Polymers
,
Therapeutics > Metabolism And Endocrinology
2017-502 Novel Targets and Use of Small Molecule BT-2 to Treat Heart Failure, Obesity and Diabetes
Novel Targets And Use Of Small Molecule BT-2 To Treat Heart Failure, Obesity And DiabetesSUMMARYUCLA researchers from the Cardiovascular Theme in the Departments of Anesthesiology, Physiology and Medicine have discovered new pathways and potential treatment options for heart failure, obesity, and diabetesBACKGROUNDHeart failure is a leading cause of...
Published: 7/19/2023
|
Inventor(s):
Yibin Wang
,
Haipeng Sun
Keywords(s):
Cardiovascular
,
Endocrinology
,
Metabolic Diseases
Category(s):
Therapeutics > Cardiovascular
,
Therapeutics > Metabolism And Endocrinology
2019-623 USE OF A NATURAL METABOLITE AS A CANCER THERAPY
UCLA Researchers in the Department of Chemistry and Biochemistry have devised a novel off label usage for the commonly available supplement s-adenylmethionine in the treatment of cancer.BACKGROUND: Tumor cells exhibit a wildly different metabolism from the tissue they are derived from. This altered metabolism allows sustained proliferation rates while...
Published: 7/19/2023
|
Inventor(s):
Steven Clarke
Keywords(s):
Metabolic Diseases
,
Oncology
,
Therapeutics & Vaccines
Category(s):
Therapeutics > Oncology
,
Therapeutics > Metabolism And Endocrinology
2020-173 BIOCHEMICAL MARKERS OF PROVOKED VESTIBULODYNIA
UCLA researchers from the Departments of Medicine and Obstetrics and Gynecology have developed novel biochemical markers of provoked vestibulodynia. BACKGROUND:Provoked vestibulodynia (PVD) is a chronic pain disorder that involves hypersensitivity and severe pain localized to the vulvar vestibule. This disorder affects approximately 7 to 16% of the...
Published: 7/19/2023
|
Inventor(s):
Jennifer Labus
,
Andrea Rapkin
,
Emeran Mayer
Keywords(s):
Diagnostic Markers & Platforms
,
Metabolic Diseases
Category(s):
Therapeutics > Metabolism And Endocrinology
2019-833 SMALL MOLECULE HETEROCYCLIC GOAT INHIBITORS
UCLA researchers have developed a potent and stable small molecule inhibitor of the ghrelin O-acyl transferase as potential therapy for obesity and type II diabetes. BACKGROUND:Obesity, and type II diabetes (T2D) resultant from obesity affect millions of people worldwide, and has reached epidemic level in society. Numerous means to counter the trend...
Published: 1/17/2024
|
Inventor(s):
Patrick Harran
Keywords(s):
Metabolic Diseases
,
Therapeutics & Vaccines
Category(s):
Therapeutics > Metabolism And Endocrinology
Smart Dialysis Catheter
UC Case No. 2019-873SUMMARY:UCLA researchers in the Department of Cardiology at UCLA’s David Geffen School of Medicine have developed a smart dialysis catheter that can measure different patient vitals in real-time to prevent hospitalizations due to renal failure.BACKGROUND:Kidney failure currently affects 660,000 Americans. 468,000 of these individuals...
Published: 7/19/2023
|
Inventor(s):
Asim Rafique
Keywords(s):
Bioinformatics
,
Cardiovascular
,
Diagnostic Platform Technologies (E.G. Microfluidics)
,
Digital Health
,
Hospital Systems And Devices
,
Medical Devices and Materials
,
Metabolic Diseases
,
Monitoring And Recording Systems
,
Renal
,
Urology
Category(s):
Medical Devices > Monitoring And Recording Systems
,
Platforms > Diagnostic Platform Technologies
,
Therapeutics > Cardiovascular
2018-199 Identification of OLMAINC as a Biomarker for NAFLD, NASH, Metabolic Syndrome, and Hepatic Fibrosis
Identification Of OLMAINC as a Biomarker for NAFLD, NASH, Metabolic Syndrome, Hepatic FibrosisSUMMARYUCLA researchers in the Departments of Medicine and Human Genetics have identified a sequence of long, non-coding RNA that plays a role in the regulation of intracellular lipogenesis and holds potential for diagnosing and treating
metabolic diseases
,...
Published: 7/19/2023
|
Inventor(s):
Jihane Benhammou
,
Paivi Pajukanta
,
Joseph Pisegna
Keywords(s):
Diagnostic Markers & Platforms
,
Metabolic Diseases
,
Therapeutics & Vaccines
Category(s):
Diagnostic Markers
,
Therapeutics
,
Therapeutics > Metabolism And Endocrinology
2013-076 Improved Treatment of Acute Metabolic Acidosis
Improved Treatment of Acute Metabolic AcidosisSUMMARYProfessors Thomas Mason and Jeffrey Kraut in UCLA’s Department of Chemistry and School of Medicine, respectively, have developed improved materials and methods of treating acute metabolic acidosis.BACKGROUNDMetabolic acidosis is a condition in which blood pH becomes abnormally acidic. It can...
Published: 7/19/2023
|
Inventor(s):
Thomas Mason
,
Jeffrey Kraut
Keywords(s):
Endocrinology
,
Metabolic Diseases
,
Therapeutics & Vaccines
Category(s):
Therapeutics
,
Therapeutics > Metabolism And Endocrinology
1
2